MONTREAL, June 26, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce high-grade silver results from its ongoing drill exploration program at the Zgounder Silver Mine and the start of its drill exploration program in the Far East permits in the Kingdom of Morocco. The Corporation has also acquired six (6) new permits to the north, expanding the Zgounder exploration footprint by 11.9% to over 452.7 square kilometers (“km2”). Highlights ...

HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (“Itafos” or “the Company”) today announces that the OTC Markets Group Inc., operator of regulated markets for trading 12,000 US and international securities, has approved the Company’s application to trade on the OTCQX® Best Market, upgrading from the Pink® market. Itafos will begin trading today on the OTCQX under the symbol “ITFS”. Trading on the OTCQX Best Market offers Itafos an efficient, cost-effective way to access th ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces a non-brokered private placement to raise up to USD $925,000 through the issuance of up to 1,267,123 common share units ...

文章核心观点 - 基因编辑公司CRISPR Therapeutics公布体内心血管疾病项目进展，包括CTX310新数据、CTX320和CTX340的持续进展 [1] 公司概况 - 公司成立超十年，从研究阶段公司发展为首个CRISPR疗法获批的领导者，产品候选组合多样，涵盖多种疾病领域 [9] - 2018年将首个CRISPR/Cas9基因编辑疗法推进到临床，2023年末起，CASGEVY在多国获批治疗特定疾病 [9] - 公司与Vertex Pharmaceuticals等领先公司建立战略伙伴关系，总部位于瑞士楚格，在美国有子公司，研发运营位于波士顿和旧金山 [9] CTX310项目 - 靶点为ANGPTL3基因，该基因编码的蛋白与LDL和TG水平调节有关，功能丧失突变可降低LDL和TG水平及ASCVD风险，美国超4000万患者受LDL或TG升高影响 [5] - 处于针对ANGPTL3的一期人体临床试验，针对四类患者群体，合格参与者有特定LDL和TG水平要求，LDL和TG是监管机构认可的替代终点 [5] - 新结果基于前四个队列前10名患者先前披露结果，目前数据显示DL4剂量下TG峰值降低达82%，LDL降低达86%，且肝脏酶无临床显著变化，安全性和耐受性与先前一致 [5] - 公司预计2025年下半年在医学会议上公布CTX310完整一期数据 [1][5] CTX320项目 - 靶点为LPA基因，针对Lp(a)升高患者，Lp(a)升高影响全球达20%人口，现有疗法无法解决 [5] - 一期试验正在招募患者并进行剂量探索，预计2026年上半年更新数据，以纳入Lp(a)治疗领域新见解 [1][5] CTX340项目 - 靶点为血管紧张素原（AGT），用于治疗难治性高血压，目前正在进行IND/CTA启用研究 [7] 体内项目平台 - 公司建立了专有的脂质纳米颗粒（LNP）平台，用于将CRISPR/Cas9递送至肝脏 [8] - 体内产品组合包括CTX310和CTX320，均为心血管疾病的有效治疗靶点，分别处于针对不同患者群体的临床试验中 [8] - 公司研究和临床前开发候选药物还包括CTX340和CTX450，分别针对难治性高血压和急性肝卟啉病 [8]

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ITAFOS INC. (TSX-V: IFOS; OTCQX: ITFS), a phosphate and specialty fertilizer company, has qualified to trade on the OTCQX® Best Market. ITAFOS INC. upgraded to OTCQX from the Pink® market. ITAFOS INC. begins trading today on OTCQX under the symbol “ITFS.” U.S. investors can find current financial disclosure and Real-Time Level 2 ...

Each party to offer Palladyne™AI’s embodied neuro-symbolic artificial intelligence Software bundled with Mobilicom’s OS3 cybersecurity solution Palo Alto, California, and Salt Lake City, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom”), a provider of cybersecurity and robust solutions for drones and robotics, and Palladyne AI Corp. (Nasdaq: PDYN) (“Palladyne AI”), a developer of embodied neuro-symbolic artificial intelligence software for robotic platforms and u ...

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® at medical conferences and a planned KOL event MDNA11 continues to exhibit compelling deep and durable anti-tumor activity in difficult-to-treat solid tumors with best-in-class potential relative to competing IL-2 programs Results presented at the 2025 AACR showed response rates in the 30-50% range in various tu ...

Lantronix Edge Intelligent Gateways and Percepxion Platform to Improve Network Resilience, Reduce Service Disruptions and Cut Operational CostsIRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity IoT solutions enabling Edge AI Intelligence, today announced a multi-year agreement with a Tier-1 U.S. mobile network operator to digitally transform the management of more than 50,000 backup power systems across wireless cell sites nationwide. ...

Groundbreaking new platform orchestrates millions of actions across warehouse, transportation and people management to drive next frontier of productivity Built using leading AI technology from Google Cloud and Snowflake GREENWICH, Conn., June 26, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced the launch of GXO IQ, the first AI-powered intelligent platform built for the logistics industry by logistics experts. GXO IQ will ...

文章核心观点 - 公司宣布发表一项科学研究，聚焦不同大麻素配方生物利用度比较，口服Tilray THC:CBD提取物配方比口腔黏膜给药的纳比西莫尔更快达到更高THC和CBD浓度，对临床应用有重要意义 [1][4] 研究内容 - 研究旨在评估两种THC:CBD配方药代动力学参数和相对生物利用度，分别为口服Tilray THC:CBD提取物和口腔黏膜给药纳比西莫尔，对12名空腹健康志愿者进行试验，采集血样计算THC、11-OH-THC和CBD药代动力学参数 [2][3] 研究结果 - Tilray THC:CBD提取物的THC和CBD的Cmax显著高于纳比西莫尔，Tmax和AUC无显著差异，纳比西莫尔在男性中的Cmax显著高于女性，两种治疗条件下24小时后THC和CBD检测不到，11-OH-THC从峰值显著降低，未报告严重不良事件 [3] 公司表态 - 医学总监称研究有助于开发提高治疗效果的配方，首席战略官表示研究体现对推进医用大麻科学的承诺，目标是为全球患者提供安全有效产品 [5] 公司概况 - Tilray Medical是全球医用大麻领导者，提供欧盟GMP认证和医药级产品，供应超20个国家，支持全球多地医学试验，研究医用大麻对多种病症的治疗效果 [1][5] - Tilray Brands是全球生活方式和消费品公司，业务覆盖多个地区，支持超40个品牌，产品包括大麻、大麻食品和精酿饮料 [8]